Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | PRKACG | P22612 | 1/20 | 0.31 |
| ▸ | PRKACB | P22694 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658606 | 1.00 | TDP2 (0.31) | TDP2SRCPRKACAPRKACGPRKACB | |
| SCHEMBL30104207 | 0.83 | ALDH1A1 (0.34) | TDP2KMT2ATMPRSS4 | |
| SCHEMBL1963833 | 0.83 | ALDH1A1 (0.34) | TDP2KMT2ATMPRSS4 | |
| SCHEMBL9929735 | 0.81 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL29664335 | 0.81 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL1960670 | 0.75 | MEN1 (0.32) | MEN1OPRK1HTTKMT2A | |
| SCHEMBL29664191 | 0.75 | MEN1 (0.32) | MEN1OPRK1HTTKMT2A | |
| SCHEMBL1815597 | 0.73 | KCNH2 (0.36) | MEN1KMT2A | |
| SCHEMBL10323482 | 0.70 | SLC6A2 (0.35) | TDP2MEN1KMT2A | |
| SCHEMBL1959954 | 0.69 | PDK2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621958-B9 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-09-25 | — | — | EP | disclosed |
| EP-3621958-B1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL LTD (IE) | 2024-07-10 | — | — | EP | disclosed |
| CN-110730778-B | Photochromic indeno-fused phenanthropyran compounds | 光学转变有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11453654-B2 | Photochromic indeno fused phenanthrenopyran compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2022-09-27 | — | — | US | disclosed |
| EP-3621958-A1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | Transitions Optical, Ltd. (IE) | 2020-03-18 | — | — | EP | disclosed |
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | TRANSITIONS OPTICAL, LTD. (IE) | 2020-02-13 | — | — | US | disclosed |
| CN-110730778-A | Photochromic indeno-fused phenanthropyran compounds | 光学转变有限公司 | 2020-01-24 | — | — | CN | disclosed |
| WO-2018206096-A1 | PHOTOCHROMIC INDENO FUSED PHENANTHRENOPYRAN COMPOUNDS | TRANSITIONS OPTICAL, LTD. (IE) | 2018-11-15 | — | — | WO | disclosed |
| EP-2651914-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8920928-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2651914-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082999-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048216-A1 | Photochromic Indeno Fused Phenanthrenopyran Compounds | ALDH1A2, RB1, INCENP | TDP2 1195/4885SRC 3340/4885PRKACA 4847/4885 |
| US-11453654-B2 | Photochromic indeno fused phenanthrenopyran compounds | ALDH1A2, RB1, INCENP | TDP2 1195/4885SRC 3340/4885PRKACA 4847/4885 |
| US-20120156508-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | CRY2, CRY1, IPO4 | TDP2 592/4885SRC 2472/4885PRKACA 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.